The UK’s National Institute for Health and Care Excellence (NICE) is recommending the use of atezolizumab (Tecentriq) for treatment-naïve patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-based therapy.
Once those data are available, atezolizumab will enter the process for exiting the CDF and a review of the NICE guidance will start. Oncotherapy drugs are only available through the CDF for a limited period.
Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67-76.
... to read the full story